Darrell S. Pardi

Darrell S. Pardi

Auto-generated profile, based on publicly available information

Darrell S. Pardi

Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
SKSahil Khanna
Sahil Khanna
DPDarrell S Pardi
Darrell S Pardi
SAScott L Aronson
Scott L Aronson
PKPatricia P Kammer
Patricia P Kammer
RORobert Orenstein
Robert Orenstein
AZAlan R Zinsmeister
Alan R Zinsmeister
Mmunity-based CDI studies, as most of the existing studies are hospital based, potentially influencing the results by referral or hospitalization bias by missing cases of community-acquired CDI. METHODS: To better understand the epidemiology of community-acquiredC. difficileinfection, a population-based study was conducted in Olmsted County, Minnesota, using the resources of the Rochester Epidemiology Project. Data regarding severity, treatment response, and outcomes were compared in community-acquired vs. hospital-acquired cohorts, and changes in these parameters, as well as in incidence, were assessed over the study period. RESULTS: Community-acquired CDI cases accounted for 41% of 385 definite CDI cases. The incidence of both community-acquired and hospital-acquired CDI increased significantly over the study period. Compared with those with hospital-acquired infection, patients with community-acquired infection were younger (median age 50 years compared with 72 years), more likely to be female (76% vs. 60%), had lower comorbidity scores, and were less likely to have severe infection (20% vs. 31%) or have been exposed to antibiotics (78% vs. 94%). There were no differences in the rates of complicated or recurrent infection in patients with community-acquired compared with hospital-acquired infection. CONCLUSIONS: In this population-based cohort, a significant proportion of cases of CDI occurred in the community. These patients were younger and had less severe infection than those with hospital-acquired infection. Thus, reports of CDI in hospitalized patients likely underestimate the burden of disease and overestimate severity....

1 April 2003 in Gastroenterology
Verified
Journal Article
Closed access
DPDarrell S. Pardi
Darrell S. Pardi
ELEdward Loftus
Edward Loftus
WKWalter K. Kremers
Walter K. Kremers
JKJill Keach
Jill Keach
KLKeith D. Lindor
Keith D. Lindor

1 March 2014 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
SSSiddharth Singh
Siddharth Singh
HSHarkirat Singh
Harkirat Singh
ELEdward Loftus
Edward Loftus
DPDarrell S. Pardi
Darrell S. Pardi

29 November 2006 in Gut
Verified
Journal Article
Closed access
DPDarrell S Pardi
Darrell S Pardi
ELEdward Loftus
Edward Loftus
TSThomas C Smyrk
Thomas C Smyrk
PKPatricia P Kammer
Patricia P Kammer
WTWilliam J Tremaine
William J Tremaine
WSWilliam J Sandborn
William J Sandborn
Objective: Although the epidemiology of microscopic colitis has been described in Europe, no such data exist from North America. We studied the incidence, prevalence and temporal trends of microscopic colitis in a geographically defined US population. Design and setting: In this population based cohort study, residents of Olmsted County, Minnesota, with a new diagnosis of microscopic colitis, and all who had colon biopsies for evaluation of diarrhoea, between 1 January 1985 and 31 December 2001 were identified. Biopsies were reviewed for confirmation (cases) and to identify missed cases (diarrhoea biopsies). Main outcome measures: Incidence rates, age and sex adjusted to the 2000 US white population. Poisson regression assessed the association of calendar period, age and sex with incidence. Results: We identified 130 incident cases for an overall rate of 8.6 cases per 100 000 person-years. There was a significant secular trend, with incidence increasing from 1.1 per 100 000 early in the study to 19.6 per 100 000 by the end (p<0.001). Rates increased with age (p<0.001). By subtype, the incidence was 3.1 per 100 000 for collagenous colitis and 5.5 per 100 000 for lymphocytic colitis. Collagenous colitis was associated with female sex (p<0.001) but lymphocytic colitis was not. Prevalence (per 100 000 persons) on 31 December 2001 was 103.0 (39.3 for collagenous colitis and 63.7 for lymphocytic colitis). Conclusions: The incidence of microscopic colitis has increased significantly over time, and by the end of the study, the incidence and prevalence were significantly higher than reported previously. Microscopic colitis is associated with older age, and collagenous colitis is associated with female sex.

1 April 2011 in Gastroenterology
Verified
Journal Article
Closed access
DPDarrell S. Pardi
Darrell S. Pardi
CKCiarán P. Kelly
Ciarán P. Kelly

15 May 2017 in Microbiome
Verified
Journal Article
Open access
PDF file
SKSahil Khanna
Sahil Khanna
YVYoshiki Vazquez-Baeza
Yoshiki Vazquez-Baeza
AGAntonio González
Antonio González
SWSophie Weiss
Sophie Weiss
BSBradley Schmidt
Bradley Schmidt
PKPurna C. Kashyap
Purna C. Kashyap
Gut microbiota play a key role in maintaining homeostasis in the human gut. Alterations in the gut microbial ecosystem predispose to Clostridium difficile infection (CDI) and gut inflammatory disorders such as inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) from a healthy donor can restore gut microbial diversity and pathogen colonization resistance; consequently, it is now being investigated for its ability to improve inflammatory gut conditions such as IBD. In this study, we investigated changes in gut microbiota following FMT in 38 patients with CDI with or without underlying IBD. There was a significant change in gut microbial composition towards the donor microbiota and an overall increase in microbial diversity consistent with previous studies after FMT. FMT was successful in treating CDI using a diverse set of donors, and varying degrees of donor stool engraftment suggesting that donor type and degree of engraftment are not drivers of a successful FMT treatment of CDI. However, patients with underlying IBD experienced an increased number of CDI relapses (during a 24-month follow-up) and a decreased growth of new taxa, as compared to the subjects without IBD. Moreover, the need for IBD therapy did not change following FMT. These results underscore the importance of the existing gut microbial landscape as a decisive factor to successfully treat CDI and potentially for improvement of the underlying pathophysiology in IBD. FMT leads to a significant change in microbial diversity in patients with recurrent CDI and complete resolution of symptoms. Stool donor type (related or unrelated) and degree of engraftment are not the key for successful treatment of CDI by FMT. However, CDI patients with IBD have higher proportion of the original community after FMT and lack of improvement of their IBD symptoms and increased episodes of CDI on long-term follow-up.